GlaxoSmithKline cancer drug suffers setback
March 20, 2014 at 05:24 AM EDT
GlaxoSmithKline says Thursday that its MAGE-A3 cancer vaccine hadn’t met its first or second co-primary endpoints in its Phase III trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.